TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21947316

Group type: EXPERIMENTAL
Intervention: D: ‐amphetamine 10 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: D: ‐amphetamine 20 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 19081638

Group type: EXPERIMENTAL
Intervention: Bifrontal ultra-brief pulse ECT at 1.5 times seizure threshold
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Unilateral ultra-brief pulse ECT at 6 times seizure threshold
Number of subjects: 81
Study: 17803464

Group type: EXPERIMENTAL
Intervention: Eprex
Number of subjects: 93

Group type: COMPARATOR
Intervention: GerEPO
Number of subjects: 93

Group type: COMPARATOR
Intervention: Comparison of Eprex and GerEPO
Number of subjects: 93
Study: 15222054

Group type: EXPERIMENTAL
Intervention: Glutamine (30 g/d for 7 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (30 g/d for 7 days)
Number of subjects: 20
Study: 15046691

Group type: EXPERIMENTAL
Intervention: Intermittent androgen deprivation (IAD)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Continuous androgen deprivation (CAD)
Number of subjects: 68
Study: 9845254

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 8566997

Group type: EXPERIMENTAL
Intervention: Auditory displays (musical graphs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Visual line graphs
Number of subjects: 0
Study: 1978470

Group type: EXPERIMENTAL
Intervention: Remoxipride 75-300 mg twice daily
Number of subjects: 89

Group type: COMPARATOR
Intervention: Haloperidol 5-20 mg twice daily
Number of subjects: 89
Study: 605682

Group type: EXPERIMENTAL
Intervention: Stopping at once
Number of subjects: 906

Group type: COMPARATOR
Intervention: Distribution of smoking cessation program over several days
Number of subjects: 906

Group type: COMPARATOR
Intervention: Extract of avena sativa
Number of subjects: 906
Study: 30472023

Group type: EXPERIMENTAL
Intervention: Pirfenidone 2,403 mg/d
Number of subjects: 1247

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1247
Study: 27886407

Group type: EXPERIMENTAL
Intervention: PRX002 (0.3, 1, 3, 10, or 30 mg/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 25471255

Group type: EXPERIMENTAL
Intervention: Regular moderate exercise during pregnancy
Number of subjects: 336

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 336
Study: 23325325

Group type: EXPERIMENTAL
Intervention: Davunetide (5 and 30 mg/day)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 21876641

Group type: EXPERIMENTAL
Intervention: Imiquimod 3.75% cream applied daily until complete clearance or a maximum of 8 weeks
Number of subjects: 534

Group type: EXPERIMENTAL
Intervention: Imiquimod 2.5% cream applied daily until complete clearance or a maximum of 8 weeks
Number of subjects: 534

Group type: COMPARATOR
Intervention: Placebo cream applied daily until complete clearance or a maximum of 8 weeks
Number of subjects: 534
Study: 19570991

Group type: EXPERIMENTAL
Intervention: Combination of aerobic plus resistance exercise (HAC)
Number of subjects: 3042
Study: 18181332

Group type: EXPERIMENTAL
Intervention: NNRTI (NVP)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: NNRTI (EFV)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: NNRTI (NVP and EFV combined)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: CD4% decrease at week 12
Number of subjects: 69
Study: 14981868

Group type: EXPERIMENTAL
Intervention: Lifestyle modification including changes in diet and activity; no specific dosage or duration mentioned.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy or surgery; details not specified.
Number of subjects: 0
Study: 11685304

Group type: EXPERIMENTAL
Intervention: MDI-NIMV (inspiratory pressure=14.3+/‐1.8 cmH2O; expiratory pressure=none)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: IPPB
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: MDI-Spacer
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: MDI-NIMV
Number of subjects: 18
Study: 9713266

Group type: EXPERIMENTAL
Intervention: Amenorrhoea after adjuvant chemotherapy
Number of subjects: 1196

Group type: EXPERIMENTAL
Intervention: Three initial CMF courses
Number of subjects: 1196

Group type: EXPERIMENTAL
Intervention: ER/PR positive tumours
Number of subjects: 1196

Group type: EXPERIMENTAL
Intervention: Temporary amenorrhoea
Number of subjects: 1196
Study: 7978210

Group type: EXPERIMENTAL
Intervention: Lignocaine cardioplegia (100 mg/l)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Lignocaine cardioplegia
Number of subjects: 141

Group type: COMPARATOR
Intervention: Control group (cardioplegia without lignocaine)
Number of subjects: 141
Study: 2730828

Group type: EXPERIMENTAL
Intervention: Nicardipine infusion
Number of subjects: 80

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 80
Study: 779298

Group type: EXPERIMENTAL
Intervention: Desoximetasone (test name A 41 304 from Hoechst Aktiengesellschaft)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Betamethasone 17-valerate preparation (control)
Number of subjects: 46
Study: 30454850

Group type: EXPERIMENTAL
Intervention: SMEDS formulation (500 mg EPA + DHA)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Standard ω-3 acid EE formulation (840 mg EPA + DHA)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: SMEDS formulation
Number of subjects: 23
Study: 25924567

Group type: EXPERIMENTAL
Intervention: Kinesio taping
Number of subjects: 31
Study: 26242295

Group type: EXPERIMENTAL
Intervention: Loading dose of vitamin D (100,000 IU on day 1, then 2 and 4 weeks after surgery) followed by maintenance dose (3420 IU/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo followed by standard dose of vitamin D (3420 IU/day)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 50
Study: 23855173

Group type: EXPERIMENTAL
Intervention: Air Abrasion + 36% Phosphoric acid-etch + Conseal F
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser + Acid Etch + Prime & Bond NT + Conseal F
Number of subjects: 144

Group type: COMPARATOR
Intervention: No pretreatment (Control) + various bonding agents
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Laser pretreatment + Acid Etch + Prime & Bond + Conseal F
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Air Abrasion pretreatment + Acid Etch + Prime & Bond + Conseal F
Number of subjects: 144
Study: 20883428

Group type: EXPERIMENTAL
Intervention: PAC (pantoprazole 40 mg b.i.d., amoxicillin 1.0 g b.i.d., clarithromycin 500 mg b.i.d. for 7 days)
Number of subjects: 170

Group type: COMPARATOR
Intervention: PBMT (pantoprazole 40 mg b.i.d., colloidal bismuth subcitrate 220 mg b.i.d, metronidazole 400 mg t.i.d., tetracycline 750 mg b.i.d. for 10 days)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: PAC
Number of subjects: 170

Group type: COMPARATOR
Intervention: PBMT
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: H. pylori strains
Number of subjects: 170
Study: 18675400

Group type: EXPERIMENTAL
Intervention: Interpretation Modification Program (IMP)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 27
Study: 15940132

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 79
Study: 12969999

Group type: EXPERIMENTAL
Intervention: Inhaled flunisolide (ICS), 1 mg, four inhalations bid for 7 days
Number of subjects: 58

Group type: COMPARATOR
Intervention: Oral prednisone (OCS), 2 mg/kg (max 60 mg/d) for 7 days
Number of subjects: 58
Study: 10372436

Group type: EXPERIMENTAL
Intervention: 1% lidocaine
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 42

Group type: COMPARATOR
Intervention: 0.9% sodium chloride
Number of subjects: 42
Study: 8768186

Group type: EXPERIMENTAL
Intervention: Afterimages of 2-8 dots
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Afterimages of 2-4 linearly configured dots
Number of subjects: 3

Group type: COMPARATOR
Intervention: Nonafterimage control conditions
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Briefly presented stimuli disabling eye movements
Number of subjects: 3
Study: 1881720

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (Ig) therapy
Number of subjects: 235

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 235
Study: 7055176

Group type: EXPERIMENTAL
Intervention: Tetracycline, 500 mg, four times daily for 7 days
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Erythromycin, 500 mg, four times daily for 7 days
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Erythromycin, 250 mg, four times daily for 7 days
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Tetracycline, 500 mg, four times daily for 10 days
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Sulfisoxazole, 500 mg, four times daily for 10 days
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Ampicillin, loading dose plus additional ampicillin for 3 to 21 days
Number of subjects: 113
Study: 31725176

Group type: EXPERIMENTAL
Intervention: RAFT (Rapid Appraisal for Trafficking) screening tool
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Qualitative data assessment by trained data collectors
Number of subjects: 0
Study: 29700801

Group type: EXPERIMENTAL
Intervention: Ketamine-based anesthesia
Number of subjects: 24

Group type: COMPARATOR
Intervention: Propofol-based anesthesia
Number of subjects: 24
Study: 27733519

Group type: EXPERIMENTAL
Intervention: 3 day cefditoren pivoxil regimen
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: 7 day cefditoren pivoxil regimen
Number of subjects: 104
Study: 24922557

Group type: EXPERIMENTAL
Intervention: Cone Beam CT (CBCT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Panoramic imaging
Number of subjects: 0
Study: 23689765

Group type: EXPERIMENTAL
Intervention: Oxandrolone, 20 mg/d (n = 108)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Placebo (n = 104)
Number of subjects: 212
Study: 19880676

Group type: EXPERIMENTAL
Intervention: CP-690,550 5 mg bid
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: CP-690,550 15 mg bid
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: CP-690,550 30 mg bid
Number of subjects: 264

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study: 18591750

Group type: EXPERIMENTAL
Intervention: Calcium intake (specific dosage and duration not mentioned)
Number of subjects: 0
Study: 16616745

Group type: EXPERIMENTAL
Intervention: Serum anti-müllerian hormone (AMH) levels in patients with premature ovarian failure (POF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serum anti-müllerian hormone (AMH) levels in patients with polycystic ovary syndrome (PCOS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serum AMH evaluation
Number of subjects: 0
Study: 14655922

Group type: EXPERIMENTAL
Intervention: Psychomotor vigilance test (PVT)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Tracking
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Grammatical reasoning (GRG) response latency
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Subjective alertness ratings
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Pretest performance ratings
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Posttest performance ratings
Number of subjects: 15
Study: 11523747

Group type: EXPERIMENTAL
Intervention: Normative education program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 8858270

Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg (evening dose)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg (morning dose)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (no famotidine)
Number of subjects: 16
Study: 8099363

Group type: COMPARATOR
Intervention: Single drug therapy for induction of remission
Number of subjects: 468

Group type: COMPARATOR
Intervention: Single drug therapy for maintenance of remission at 6 months
Number of subjects: 468

Group type: COMPARATOR
Intervention: Single drug therapy for maintenance of remission at 12 months
Number of subjects: 468
Study: 3548009

Group type: EXPERIMENTAL
Intervention: Butorphanol 4 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Butorphanol 2 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Meperidine 80 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Butorphanol (4 mg) vs Meperidine (80 mg)
Number of subjects: 120
Study: 30063488

Group type: EXPERIMENTAL
Intervention: Bioimpedance spectroscopy intervention
Number of subjects: 1443

Group type: COMPARATOR
Intervention: Normal clinical practice (control)
Number of subjects: 1443
Study: 27875542

Group type: EXPERIMENTAL
Intervention: PC101 management tool training and expanded prescribing authority for nurses
Number of subjects: 4393
Study: 24583632

Group type: EXPERIMENTAL
Intervention: WEBCARE intervention
Number of subjects: 146

Group type: COMPARATOR
Intervention: Usual Care group
Number of subjects: 146
Study: 24011464

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy on one side of the jaw
Number of subjects: 10

Group type: COMPARATOR
Intervention: Non-treated side (control)
Number of subjects: 10
Study: 22950883

Group type: EXPERIMENTAL
Intervention: SC counselling arm (363 participants)
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: SC + PA counselling arm (366 participants)
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Control group (371 participants)
Number of subjects: 1100
Study: 19956085

Group type: EXPERIMENTAL
Intervention: 150 mg DMXB-A
Number of subjects: 16

Group type: COMPARATOR
Intervention: 75 mg DMXB-A
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 17335057

Group type: EXPERIMENTAL
Intervention: Detection of Ljungan virus (LV) in brain tissue
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Detection of Ljungan virus (LV) in placenta
Number of subjects: 10
Study: 15895328

Group type: EXPERIMENTAL
Intervention: Function-centered treatment (FCT) (4h/d, 6d/wk, for 3 wk)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Pain-centered treatment (PCT) (2.5h/d, 6d/wk, for 3 wk)
Number of subjects: 174
Study: 12126662

Group type: EXPERIMENTAL
Intervention: Rectus femoris transfer surgery
Number of subjects: 16

Group type: COMPARATOR
Intervention: Unimpaired control subjects
Number of subjects: 16
Study: 10443771

Group type: EXPERIMENTAL
Intervention: Glucose (50 g)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saccharin (50 mg)
Number of subjects: 0
Study: 8675378

Group type: EXPERIMENTAL
Intervention: Audiotape of information focusing on expected physical symptoms and their management in addition to usual care
Number of subjects: 82

Group type: COMPARATOR
Intervention: Usual cardiac discharge information protocol
Number of subjects: 82
Study: 1611017

Group type: EXPERIMENTAL
Intervention: Cholecystokinin octapeptide (CCK‐8, 0.06 microgram/kg)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 6391504

Group type: EXPERIMENTAL
Intervention: Praziquantel (25 mg per kg of body weight, 3 times daily for one or two days)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Praziquantel (two-day dosage schedule)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Praziquantel (one-day dosage schedule)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Praziquantel (both dosages)
Number of subjects: 67
Study: 31775808

Group type: EXPERIMENTAL
Intervention: Intra-substance injection with Diprospan (1 cc) and 1% xylocaine (1 cc)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Normal saline (1 cc) and 1% xylocaine (1 cc)
Number of subjects: 24
Study: 30572588

Group type: EXPERIMENTAL
Intervention: Replacing 5% energy from saturated fatty acids (SFA) with monounsaturated fatty acids (MUFA)
Number of subjects: 6942

Group type: EXPERIMENTAL
Intervention: Replacing 5% energy from saturated fatty acids (SFA) with polyunsaturated fatty acids (PUFA)
Number of subjects: 6942

Group type: EXPERIMENTAL
Intervention: Replacing proteins with MUFA or PUFA
Number of subjects: 6942

Group type: EXPERIMENTAL
Intervention: Daily substitution of one portion of red meat with white meat, oily fish or white fish
Number of subjects: 6942

Group type: EXPERIMENTAL
Intervention: Increasing intake of unsaturated fatty acids at the expense of SFA, proteins, and carbohydrates
Number of subjects: 6942
Study: 27349575

Group type: EXPERIMENTAL
Intervention: Patients with IBS and positive anti‐tTG results (Group II, 8 patients)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Patients with IBS and negative anti‐tTG results (Group I, 92 patients)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Patients with IBS and positive anti‐tTG results (Group II)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Patients with IBS and negative anti‐tTG results (Group I)
Number of subjects: 100
Study: 24794879

Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 485

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 485
Study: 22791755

Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol-cyproterone acetate (EE-CA)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Low-dose pioglitazone (7.5 mg/d), flutamide (62.5 mg/d), and metformin (850 mg/d) (PioFluMet)
Number of subjects: 34
Study: 20004655

Group type: EXPERIMENTAL
Intervention: Slow eating pace
Number of subjects: 24

Group type: COMPARATOR
Intervention: Normal eating pace
Number of subjects: 24
Study: 16954331

Group type: EXPERIMENTAL
Intervention: Intravenous microdialysis of N(G)-nitro-l-arginine methyl ester (l-NAME; NO synthase inhibitor) during local warming to 42 degrees C
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) for assessment of maximum cutaneous vascular conductance (CVC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Local warming to 42 degrees C
Number of subjects: 0
Study: 15848573

Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 260
Study: 11914932

Group type: EXPERIMENTAL
Intervention: 20 mg NSC‐631570
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 1000 mg gemcitabine/m2 followed by 20 mg NSC‐631570 weekly
Number of subjects: 90

Group type: COMPARATOR
Intervention: 1000 mg gemcitabine/m2
Number of subjects: 90
Study: 10382476

Group type: EXPERIMENTAL
Intervention: Midwife-managed care
Number of subjects: 1299

Group type: COMPARATOR
Intervention: Shared care
Number of subjects: 1299
Study: 7617115

Group type: EXPERIMENTAL
Intervention: Hypocaloric diets
Number of subjects: 17

Group type: COMPARATOR
Intervention: Captopril treatment
Number of subjects: 17
Study: 1320917

Group type: EXPERIMENTAL
Intervention: Oral granisetron 1.0 mg twice daily
Number of subjects: 930

Group type: COMPARATOR
Intervention: Oral granisetron 0.25 mg twice daily
Number of subjects: 930

Group type: COMPARATOR
Intervention: Oral granisetron 0.5 mg twice daily
Number of subjects: 930

Group type: EXPERIMENTAL
Intervention: Adverse events (constipation, headache, abdominal pain, fever, leucopenia, asthenia)
Number of subjects: 930
Study: 6824435

Group type: EXPERIMENTAL
Intervention: AM clipper method
Number of subjects: 1013

Group type: COMPARATOR
Intervention: Shaving
Number of subjects: 1013
Study: 31470240

Group type: EXPERIMENTAL
Intervention: ECIG+OB (18 ng/ml nicotine)
Number of subjects: 60

Group type: COMPARATOR
Intervention: OB-only
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 29756979

Group type: EXPERIMENTAL
Intervention: Glutamine (10 g every 8 hours)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Control (no glutamine)
Number of subjects: 262
Study: 25091553

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) infusion with standard treatment
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard treatment only
Number of subjects: 48
Study: 24125895

Group type: EXPERIMENTAL
Intervention: FACT-G
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: QLQ-C30
Number of subjects: 162
Study: 22553251

Group type: EXPERIMENTAL
Intervention: Gammaretroviral vector-engineered T cells (CD4ζ)
Number of subjects: 500
Study: 19560110

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 0
Study: 17623016

Group type: EXPERIMENTAL
Intervention: Indomethacin plus statin (10 mg of rosuvastatin)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Indomethacin plus placebo
Number of subjects: 55
Study: 15793417

Group type: EXPERIMENTAL
Intervention: Vestibulo-ocular reflex gaze stabilization exercises (started 3 days after surgery)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Balance physiotherapy
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (27 patients)
Number of subjects: 65
Study: 15259388

Group type: EXPERIMENTAL
Intervention: No-delay prosaccade condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No-delay antisaccade condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delay tasks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spatial working memory task
Number of subjects: 0
Study: 9856707

Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural (CSE) analgesia
Number of subjects: 1223

Group type: COMPARATOR
Intervention: Intravenous meperidine
Number of subjects: 1223
Study: 7789138

Group type: EXPERIMENTAL
Intervention: Reduction of Cardiac Operative Risk (RCOR) Trial
Number of subjects: 0
Study: 2695875

Group type: EXPERIMENTAL
Intervention: 125I brachytherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Helium ion irradiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 0
Study: 1107604

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil and cyclophosphamide
Number of subjects: 33

Group type: COMPARATOR
Intervention: adriamycin and cyclophosphamide
Number of subjects: 33
Study: 30715451

Group type: EXPERIMENTAL
Intervention: Children with a BCG scar
Number of subjects: 2213

Group type: EXPERIMENTAL
Intervention: Children with a BCG scar whose mothers also had a BCG scar
Number of subjects: 2213

Group type: COMPARATOR
Intervention: Children with no BCG scar whose mothers had no BCG scar
Number of subjects: 2213
Study: 31332700

Group type: EXPERIMENTAL
Intervention: LVEDP-guided hydration
Number of subjects: 114

Group type: COMPARATOR
Intervention: Standard hydration
Number of subjects: 114
Study: 28545545

Group type: EXPERIMENTAL
Intervention: Focused ethnography observations and staff interviews
Number of subjects: 0